DoubleGrazing (talk | contribs) Declining submission: corp - Submission is about a company or organization not yet shown to meet notability guidelines (AFCH) |
Citation bot (talk | contribs) Altered pages. Add: doi, date. Formatted dashes. | Use this bot. Report bugs. | Suggested by Лисан аль-Гаиб | #UCB_webform 132/291 |
||
Line 9: | Line 9: | ||
Sonelokimab is an investigational Nanobody designed to treat inflammatory diseases by inhibiting the naturally occurring IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation.<ref>{{Cite web |title=MoonLake Immunotherapeutics announces landmark phase 2 results |url=https://ir.moonlaketx.com/news-releases/news-release-details/moonlake-immunotherapeutics-announces-landmark-phase-2-results}}</ref> In addition, Sonelokimab is designed to directly target sites of inflammation and penetrate difficult-to-reach inflamed tissues.<ref>{{Cite web |title=MoonLake Immunotherapeutics announces publication Lancet |url=https://ir.moonlaketx.com/news-releases/news-release-details/moonlake-immunotherapeutics-announces-publication-lancet}}</ref> |
Sonelokimab is an investigational Nanobody designed to treat inflammatory diseases by inhibiting the naturally occurring IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation.<ref>{{Cite web |title=MoonLake Immunotherapeutics announces landmark phase 2 results |url=https://ir.moonlaketx.com/news-releases/news-release-details/moonlake-immunotherapeutics-announces-landmark-phase-2-results}}</ref> In addition, Sonelokimab is designed to directly target sites of inflammation and penetrate difficult-to-reach inflamed tissues.<ref>{{Cite web |title=MoonLake Immunotherapeutics announces publication Lancet |url=https://ir.moonlaketx.com/news-releases/news-release-details/moonlake-immunotherapeutics-announces-publication-lancet}}</ref> |
||
In May 2021, positive results of a Phase IIb trial of Sonelokimab for the treatment of patients with moderate to severe psoriasis were published in the peer-reviewed medical journal, The Lancet.<ref>{{Cite journal |last=Papp |first=K.A. |title=IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study |url=http://www.thelancet.com |journal=[[The Lancet]] |volume=397 |issue=10284 |pages= |
In May 2021, positive results of a Phase IIb trial of Sonelokimab for the treatment of patients with moderate to severe psoriasis were published in the peer-reviewed medical journal, The Lancet.<ref>{{Cite journal |last=Papp |first=K.A. |title=IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study |url=http://www.thelancet.com |journal=[[The Lancet]] |date=2021 |volume=397 |issue=10284 |pages=1564–1575|doi=10.1016/S0140-6736(21)00440-2 }}</ref> |
||
MoonLake is progressing the clinical development of Sonelokimab for the treatment of inflammatory diseases, including hidradenitis suppurativa<ref>{{Cite web |title=Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa |url=https://clinicaltrials.gov/study/NCT05322473}}</ref> and psoriatic arthritis.<ref>{{Cite web |title=Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis |url=https://clinicaltrials.gov/study/NCT05640245}}</ref> |
MoonLake is progressing the clinical development of Sonelokimab for the treatment of inflammatory diseases, including hidradenitis suppurativa<ref>{{Cite web |title=Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa |date=13 November 2023 |url=https://clinicaltrials.gov/study/NCT05322473}}</ref> and psoriatic arthritis.<ref>{{Cite web |title=Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis |date=15 November 2023 |url=https://clinicaltrials.gov/study/NCT05640245}}</ref> |
||
In April 2022, MoonLake combined with Helix Acquisition Corp., a special purpose acquisition vehicle, becoming a Nasdaq-listed company with the ticker symbol MLTX.<ref>{{Cite web |title=MoonLake Immunotherapeutics AG announces closing business |url=https://ir.moonlaketx.com/news-releases/news-release-details/moonlake-immunotherapeutics-ag-announces-closing-business}}</ref> |
In April 2022, MoonLake combined with Helix Acquisition Corp., a special purpose acquisition vehicle, becoming a Nasdaq-listed company with the ticker symbol MLTX.<ref>{{Cite web |title=MoonLake Immunotherapeutics AG announces closing business |url=https://ir.moonlaketx.com/news-releases/news-release-details/moonlake-immunotherapeutics-ag-announces-closing-business}}</ref> |
Revision as of 02:17, 27 March 2024
MoonLake Immunotherapeutics (‘MoonLake’) is a clinical-stage biopharmaceutical company, headquartered in Zug, Switzerland, focused on developing medicines for inflammatory diseases. The Company was founded in 2021 when Sonelokimab was in-licensed from Merck KGaA, of Darmstadt, Germany.[1] The initial investors were BVF Partners LP, Merck KGaA, Florian Schönharting, Simon Sturge, Arnout Ploos van Amstel, Dr. Jorge Santos da Silva, and Dr. Kristian Reich.[2][3]
Sonelokimab is an investigational Nanobody designed to treat inflammatory diseases by inhibiting the naturally occurring IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation.[4] In addition, Sonelokimab is designed to directly target sites of inflammation and penetrate difficult-to-reach inflamed tissues.[5]
In May 2021, positive results of a Phase IIb trial of Sonelokimab for the treatment of patients with moderate to severe psoriasis were published in the peer-reviewed medical journal, The Lancet.[6]
MoonLake is progressing the clinical development of Sonelokimab for the treatment of inflammatory diseases, including hidradenitis suppurativa[7] and psoriatic arthritis.[8]
In April 2022, MoonLake combined with Helix Acquisition Corp., a special purpose acquisition vehicle, becoming a Nasdaq-listed company with the ticker symbol MLTX.[9]
References
- ^ "MoonLake licensing and launch".
- ^ "sec.gov, shareholders' agreement".
- ^ "sec.gov, prelim. proxy statement".
- ^ "MoonLake Immunotherapeutics announces landmark phase 2 results".
- ^ "MoonLake Immunotherapeutics announces publication Lancet".
- ^ Papp, K.A. (2021). "IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study". The Lancet. 397 (10284): 1564–1575. doi:10.1016/S0140-6736(21)00440-2.
- ^ "Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa". 13 November 2023.
- ^ "Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis". 15 November 2023.
- ^ "MoonLake Immunotherapeutics AG announces closing business".